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 Introduction 
 Pancreatic cancer (PC) is a disease still characterized 
by its unfavorable outcome. The overall median survival 
is 3–5 months with a 1-year survival rate of less than 10% 
 [1] . More than 80% of patients are initially diagnosed in 
an advanced stage of disease, where the potential curative 
resection is no longer possible. Therefore, in most of the 
patients the first treatment goal is control of disease-re-
lated symptoms and prolongation of survival. Known 
prognostic factors for survival are the stage of disease, 
degree of tumor cell differentiation, weight loss, perfor-
mance status and primary tumor site  [2, 3] . 
 The diagnosis of PC is usually established based on 
imaging techniques like ultrasound, computerized to-
mography (CT) or magnetic resonance imaging and a 
subsequent histological confirmation. A known phe-
nomenon that complicates tumor imaging (especially in 
CT scan) is the desmoplastic stroma reaction induced by 
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 Abstract 
 In pancreatic cancer (PC) accurate determination of treat-
ment response by imaging often remains difficult. Various 
efforts have been undertaken to investigate new factors 
which may serve as more appropriate surrogate parameters 
of treatment efficacy. This review focuses on the role of car-
bohydrate antigen 19-9 (CA 19-9) as a prognostic tumor 
marker in PC and summarizes its contribution to monitoring 
treatment efficacy. We undertook a Medline/PubMed litera-
ture search to identify relevant trials that had analyzed the 
prognostic impact of CA 19-9 in patients treated with sur-
gery, chemoradiotherapy and chemotherapy for PC. Addi-
tionally, relevant abstract publications from scientific meet-
ings were included. In advanced PC, pretreatment CA 19-9 
levels have a prognostic impact regarding overall survival. 
Also a CA 19-9 decline under chemotherapy can provide 
prognostic information for median survival. A 20% reduc-
tion of CA 19-9 baseline levels within the first 8 weeks of 
chemotherapy appears to be sufficient to define a prognos-
tic relevant subgroup of patients (‘CA 19-9 responder’). It still 
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the tumor itself in surrounding soft tissue  [4] . Often, this 
desmoplastic reaction makes it difficult to differentiate 
normal pancreas, local inflammation and fibrosis from 
malignant tissue and therefore imaging may sometimes 
be inaccurate in the assessment of treatment response. 
Thus, other clinical endpoints and surrogate markers of 
treatment efficacy like the term ‘clinical benefit response’ 
were created (defined as a composite endpoint consisting 
of pain, analgesic consumption, performance status and 
weight  [5] ), which may be more appropriate than assess-
ment of tumor diameters. Furthermore, there have also 
been studies that try to establish a definition of treatment 
response according to changes in the levels of serum tu-
mor markers like carbohydrate antigen 19-9 (CA 19-9). 
 CA 19-9 is a tumor-associated antigen (first described 
by Koprowski et al.  [6, 7] ) defined by a monoclonal anti-
body (1116 NS 19-9) which was produced by a hybridoma 
prepared from mouse spleen, immunized with a human 
colorectal carcinoma cell line. CA 19-9 is the sialylated 
Lewis (Le) a  blood group antigen and individuals with an 
Le a–b–  phenotype (lacking the Lewis antigen glycosyl-
tranferase) are unable to synthesize CA 19-9  [8] . The di-
agnostic value in patients with suspected PC was evalu-
ated in several studies, showing a sensitivity and speci-
ficity of the CA 19-9 assay of about 70 and 80%, 
respectively  [9–12] . In addition, serial changes in CA 
19-9 levels can also provide useful diagnostic informa-
tion in patients with PC  [13] . Several reports have shown 
a significant correlation of CA 19-9 serum levels with dif-
ferent stages of disease and resectability of the tumor  [11, 
14, 15] . In about 60–80% of patients with locally advanced 
or metastatic disease elevated CA 19-9 levels are found. 
 Nevertheless, a definite role of CA 199 as a surrogate 
marker for treatment efficacy in the clinical course of pa-
tients with PC has not yet been defined. Especially the 
interpretation of serial tumor marker kinetics during 
therapy is uncertain and needs further validation. The 
focus of this review article is based on the prognostic val-
ue of serum CA 19-9 levels, with special regard to the im-
pact of CA 19-9 changes during therapy on treatment 
outcome. 
 Prognostic Value of CA 19-9 in Patients Undergoing 
Surgery for PC 
 Importance of Preoperative CA 19-9 
 The association between serum tumor marker levels 
and outcome was first established in patients undergoing 
surgery for pancreatic adenocarcinoma. A significant 
difference in survival was shown between patients with 
preoperative CA 19-9 levels higher or lower than 370 U/
ml (4.4 vs. 9.5 months, p  ! 0.01), if the stage of the disease 
was not taken into account. A statistical difference in me-
dian survival was found only in patients with stage II and 
III disease and a CA 19-9 cutoff level of 370 U/ml  [16] . 
Also, with a preoperative CA 19-9 cutoff level of 200 U/
ml, significant differences in median survival between 
the two groups were demonstrated (22 vs. 8 months,  [17] ) 
( table 1 ).  
 Importance of Postoperative CA 19-9 
 Similar to these results, postoperative CA 19-9 levels 
appear to have an influence on survival in patients with 
PC. In the long-term follow-up of 75 patients after cura-
tive resection for pancreatic ductal adenocarcinoma, high 
postoperative CA 19-9 levels were – beside adjuvant treat-
ment, T sage and nodal status – a significant prognostic 
Authors n CA 19-9 cutoff
level, U/ml
Median survival, months
Lundin et al. [16], 1994 160 370a 9.5 vs. 4.4 (p < 0.01)
Sperti et al. [17], 1993 30 200a 22.0 vs. 8.0 (p < 0.001)
Katz et al. [28], 1998 104 680b 20.0 vs. 8.0 (p = 0.0003)
Ikeda et al. [31], 2001 55 1,000b 10.3 vs. 7.2 (p = 0.04)
Micke et al. [32], 2003 95 420b 12.3 vs. 7.1 (p = 0.0056)
Saad et al. [47], 2002 28 1,212c 14.9 vs. 7.4 (p = 0.0013)
Maisey et al. [52], 2005 154 958c 11.2 vs. 5.5 (p = 0.0004)
a Preoperative CA 19-9 in patients undergoing surgery.
b Pretreatment CA 19-9 in patients receiving CRT.
c Pretreatment CA 19-9 in patients receiving systemic chemotherapy.
 
 Table 1. Prognostic value of pretreatment 
CA 19-9 
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factor for overall survival in univariate analysis  [18] . Pa-
tients whose elevated postresection CA 19-9 values nor-
malized ( ! 37 U/ml) after surgical resection not only 
had a longer median overall survival but were also char-
acterized by a prolonged disease-free survival  [19] . The 
observation that normalizing CA 19-9 levels (usually 
defined as  ! 37 U/ml) after surgery are a significant 
prognostic factor for overall survival was confirmed by 
other groups as well  [15, 17, 20, 21] . The decline of ele-
vated CA 19-9 levels back to a normal range after sur-
gery may also be stage dependent: one study showed that 
in patients with stage I, II and III of disease, CA 19-9 
values normalized only in 29, 13 and 10% of patients, 
respectively  [20] .  
 Neoadjuvant Chemoradiotherapy 
 In the neoadjuvant treatment setting for potentially 
resectable PC, a significant correlation between disease 
control and CA 19-9 decrease after 5-fluorouracil (5-
FU)-based chemoradiotherapy (CRT) was found by Wil-
let et al.  [22] . In their study, only 21% of patients with 
declining CA 19-9 levels after irradiation demonstrated 
metastases or local tumor progression whereas 90% of 
patients with increasing CA 19-9 values had disease pro-
gression. Pretreatment serum CA 19-9 levels before neo-
adjuvant CRT may, furthermore, play a role in predicting 
resectability of the tumor and survival as indicated by a 
retrospective analysis in 86 patients  [23] .  
 Prognostic Impact of CA 19-9 Kinetics 
 Another possible option for studying the prognostic 
value of CA 19-9 is the analysis of changes in its time 
course (e.g. doubling time) during the clinical course of 
patients with PC. A significant correlation between CA 
19-9 doubling time and median survival was found in 
patients with inoperable PC and in patients with pallia-
tive operation, whereas in patients with recurrence no 
correlation was noted  [24] . Already Tian et al.  [21]  have 
reported a significant linear correlation (r = 0.5) between 
survival time and doubling time of serum CA 19-9 levels 
in 15 patients undergoing surgery, indicating that CA 
19-9 kinetics may be an additional useful tool for obtain-
ing prognostic information in the clinical course of a pa-
tient with PC. 
 CA 19-9 and CRT 
 Radiation therapy and specifically combined CRT are 
effective treatment options in the multidisciplinary treat-
ment of PC. Besides neoadjuvant treatment approaches, 
particularly adjuvant CRT after surgery and primary 
CRT for locally advanced disease were studied in several 
clinical trials  [25–27] . In a retrospective analysis of a het-
erogeneous collective of 104 patients (undergoing neoad-
juvant, adjuvant and palliative CRT), CA 19-9 levels at 
the time of diagnosis were found to be a significant prog-
nostic indicator on univariate and on multivariate analy-
sis. Patients with pretreatment values greater than the 
median of 680 U/ml had a survival of only 8 months com-
pared to patients with levels below 680 U/ml, having a 
median survival of 20 months ( table 1 ). Also the post-
treatment nadir of CA 19-9 showed a significant associa-
tion with median survival. Katz et al.  [28]  additionally 
demonstrated that patients with a decrease of CA 19-9 
levels  1 75% (in response to treatment) had a statistically 
significant longer survival rate compared to patients with 
a CA 19-9 decline of  ! 75% ( table 2 ).  
 CA 19-9 and CRT for Locally Advanced Disease 
 In patients with locally advanced and unresectable 
PC, a biochemical treatment response monitored by se-
Authors n Definition of response
(CA 19-9 reduction), %
Median overall survival, months
responder nonresponder
Katz et al. [28], 1998 104 >75a 23.0 8.0 (p = 0.003)
Okusaka et al. [29], 1998 34 >50b 10.6 4.1 (p: n.a.)
Micke et al. [32], 2003 59 decreasingb, c 13.9 6.0 (p = 0.0002)
n.a. = Not available.
a Patients undergoing neoadjuvant, adjuvant and palliative CRT.
b Patients receiving CRT for locally advanced PC.
c Patients with decreasing CA 19-9 levels during treatment.
 
 Table 2. Impact of CA19-9 response to 
CRT on survival 
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rum CA 19-9 levels seems to have a prognostic impact on 
survival. Okusaka et al.  [29]  defined a CA 19-9 respond-
er under radiotherapy for unresectable disease as a pa-
tient whose serum CA 19-9 level was reduced by more 
than 50% of the pretreatment baseline level after treat-
ment. Out of 34 patients in their analysis 21% were clas-
sified as CA 19-9 responder. These responders had a lon-
ger median survival after radiation therapy than nonre-
sponders ( table 2 ). There was also a relationship between 
objective response and tumor marker response in this 
study. In the group of CA 19-9 responders, none of the 6 
patients had progressive disease during the observation 
period, and all 5 patients with tumor progression were 
classified as CA 19-9 nonresponders. Similar to this ob-
servation, Wilkowski et al.  [30]  defined a (biochemical) 
partial response as a decline of  1 50% in CA 19-9 serum 
levels in 171 patients under CRT for locally advanced dis-
ease. In this trial, the biochemical response status had no 
impact on overall survival and also the pretreatment CA 
19-9 values did not predict response or progression-free 
survival. Only patients without elevated CA 19-9 serum 
levels had a significantly longer progression-free and 
overall survival.  
 Regarding the significance of baseline CA 19-9 levels 
in patients receiving CRT, Ikeda et al.  [31] identified the 
pretreatment CA 19-9 value to be a significant prognostic 
factor in univariate (see  table 1 ) as well as in multivariate 
(HR 2.17, p = 0.02) analysis of 55 patients with locally ad-
vanced PC undergoing treatment with 5-FU- or cisplat-
in-based CRT. Micke et al.  [32] evaluated the influence of 
pre- and posttreatment CA 19-9 levels in 95 patients 
treated with CRT on outcome using the median CA 19-9 
values of all patients as cutoff point. This group demon-
strated that pretreatment levels of less than the median 
(420 U/ml) were significantly associated with a better ob-
jective tumor response (12.8 vs. 45.8%, p = 0.003) and 
overall survival (7.1 vs. 12.3 months, see  table 1 ) in pa-
tients with unresectable disease. Patients with posttreat-
ment CA 19-9 of less than the median (293 U/ml) had a 
longer median survival than patients with levels above 
the median. Additionally, patients with no decline in CA 
19-9 during therapy had a significantly lower response 
rate. On multivariate analysis, pre- and posttreatment 
values as well as a tumor marker decrease during therapy 
were independent prognostic factors for overall survival 
( table 2 )  [32] .  
 CA 19-9 and Systemic Chemotherapy 
 For patients with metastatic PC, palliative chemother-
apy is the treatment of choice. Up till now, a systemic 
monotherapy with the nucleoside analog gemcitabine 
was regarded as the standard of care for patients with ad-
vanced stages of disease  [33] . Combinations of gemcitabi-
ne with other cytostatic drugs in randomized trials have 
not yet shown any superior results concerning overall 
survival compared to single-agent gemcitabine  [34, 35] . 
Adding the EGFR tyrosine kinase inhibitor erlotinib to 
gemcitabine seems to be the first combination regimen 
that significantly improves survival  [36] . In patients 
treated with chemotherapy, the serum tumor marker CA 
19-9 can potentially provide the following prognostic in-
formation: CA 19-9 values before and after treatment as 
well as CA 19-9 kinetics may have a prognostic impact, 
e.g. on survival, and dynamic changes of CA 19-9 levels 
during treatment may also be a biochemical surrogate 
marker for objective tumor response or progression (as 
determined by imaging criteria). In several clinical phase 
II trials, a reduction of CA 19-9 tumor marker levels un-
der chemotherapy was described. A CA 19-9 decline 
 6 50% (according to baseline levels) was seen in 26–62% 
of all study patients treated with different chemotherapy 
regimens (as shown in  table 3 )  [37–43] .  
 Pretreatment CA 19-9 Level 
 As in surgery or CRT, in patients receiving systemic 
chemotherapy CA 19-9 baseline values may provide prog-
nostic information. In a trial of Saad et al.  [47]  patients 
with pretreatment CA 19-9 levels below the median of the 
entire sample had a longer median survival than patients 
with levels above the median of 1,212 U/ml ( table 1 ). On 
multivariate analysis, the pretreatment CA 19-9 level was 
an independent and highly significant predictor of sur-
vival (p = 0.0005) and even a stronger one than a CA 19-
9 response during chemotherapy (p = 0.0497). Maisey et 
al.  [52]  recently confirmed these data on a large set of 154 
patients receiving 5-FU- and/or gemcitabine-based che-
motherapy for advanced PC. In their multivariate analy-
sis, baseline CA 19-9 levels above or below the median 
value of 958 U/ml were found to be an independent prog-
nostic factor for overall survival (HR 1.8, p = 0.0004, see 
 table 1 ). Up to now, only one of all the published phase III 
trials reported – in an analysis for prognostic factors – 
that in a group of 326 patients with advanced PC, baseline 
CA 19-9 levels ( 1 350 U/ml) were found to be a significant 
prognostic parameter on univariate as well as on multi-
variate analysis  [53] . 
 CA 19-9 as Tumor Marker in Pancreatic 
Cancer 
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 Impact of CA 19-9 Kinetics during Chemotherapy on 
Survival 
 Several clinical trials addressed the question of wheth-
er decreasing CA 19-9 serum levels during chemothera-
peutic treatment have an influence on survival. Sawaki et 
al.  [50]  reported that patients treated with gemcitabine 
and decreasing CA 19-9 levels had a significantly longer 
survival than patients with increasing CA 19-9 levels dur-
ing therapy (10.2 vs. 3.7 months, p  ! 0.001). Previously, 
several investigators have tried to establish – similar to 
this observation – a definition of a biochemical treatment 
response (by reduction of CA 19-9 levels under chemo-
therapy), thereby correlating this response with median 
overall survival (as shown in  table 4 ). Ishii et al.  [44]  in 
1997 was the first author who defined a ‘CA 19-9 re-
sponder’ as a patient whose serum CA 19-9 level was re-
duced by more than 50% of the pretreatment level within 
2 months after treatment. According to this definition, 
Stemmler et al.  [48]  showed that among patients with PC 
receiving a combination chemotherapy with gemcitabine 
and cisplatin CA 19-9 responders survived significantly 
longer than CA 19-9 nonresponders (295 vs. 174 days, 
p = 0.022). Saad et al.  [47]  defined a CA 19-9 responder 
using the same cutoff level (CA 19-9 decline  1 50%) but 
at any time after the initiation of treatment. In this study, 
patients with PC under treatment with single-agent gem-









Philip et al. [37], 2001 Gem/cisplatin 62 62 5.4
Sherman and Fine [38], 2001 Gem/docetaxel 47 40 n.a.
Rocha Lima et al. [39], 2002 Gem/irinotecan 30 56 2.8
Stathopoulos et al. [40], 2004 Gem/capecitabine 39a 60 6.5
Lee et al. [41], 2004 Gem/uracil-tegafur 57 41 4.2
Cantore et al. [42], 2004 irinotecan/oxaliplatin 26 33 4.1
Milella et al. [43], 2004 celecoxib/5-FU 33 24 2.0
Gem = Gemcitabine; DCR = disease control rate, i.e. all patients achieving a remission or stable disease; 
TTP = median time to tumor progression; n.a. = not available.
a CA 19-9 decrease in patients with increased baseline levels (not defined as 650%).
 
Authors n Definition of response
(CA 19-9 reduction), %
Median overall survival, months
responder nonresponder
Ishii et al. [44], 1997 66   >50 4.7 2.9 (p: n.a.)
Gogas et al. [45], 1998 35 615a 11.1 6.2 (p = 0.001)
Halm et al. [46], 2000 43 >20 8.9 3.7 (p < 0.001)
Saad et al. [47], 2002 28 650 13.8 8.0 (p = 0.0272)
Stemmler et al. [48], 2003 87   >50 9.8 5.8 (p = 0.022)
615 9.0 4.8 (p = 0.017)
Ziske et al. [49], 2003 46   >20 12.8 8.1 (p = 0.006)
Sawaki et al. [50], 2004 40   decreasingb 10.2 3.7 (p < 0.001)
Ko et al. [51], 2005 76   >25 9.61 4.64 (p < 0.001)
  >50 10.8 5.82 (p < 0.001)
  >75 12.0 6.0 (p < 0.001)
n.a. = Not available.
a Definition of nonresponder: patients with a CA 19-9 increase >15% during therapy.
b Patients with decreasing CA 19-9 levels during treatment.
 
 Table 4. Impact of CA19-9 response to 
chemotherapy on survival 
 Boeck  /Stieber  /Holdenrieder  /Wilkowski  /
Heinemann  
 
 Oncology 2006;70:255–264 260
citabine that fulfilled the criteria of a CA 19-9 responder 
lived significantly longer than a CA 19-9 nonresponder 
(13.8 vs. 8 months, p = 0.0272). The study of Ko et al.  [51] 
 recently showed that a CA 19-9 decline of  1 25,  1 50 as well 
as  1 75% during therapy is able to define subgroups of pa-
tients with a significant survival benefit compared to pa-
tients not responding with a CA 19-9 decrease under che-
motherapy with fixed-dose rate gemcitabine. 
 In a retrospective study of 35 patients treated with the 
ECF regimen (epirubicin, cisplatin, 5-FU), a significant 
difference in median survival for patients with a CA 19-9 
decrease  1 15% compared to patients with a CA 19-9 in-
crease  1 15% on two consecutive occasions 3 weeks apart 
(333 vs. 185 days, p = 0.001) was observed  [45] . Other 
groups used a CA 19-9 decrease of  1 20% of pretreatment 
levels after 8 weeks of treatment as a cutoff point to define 
a group of patients classified as CA 19-9 responders. Pa-
tients with advanced PC and a CA 19-9 decrease  1 20% of 
baseline CA 19-9 levels after 8 weeks of gemcitabine treat-
ment had a significantly longer median survival than pa-
tients with a rise or a decrease  ^  20% (268 vs. 110 days, 
p  ! 0.001) in a study published by Halm et al.  [46]  in 2000. 
These results (with the same definition of a CA 19-9 re-
sponse) were confirmed by Ziske et al.  [49] and in both 
studies, not only median survival was significantly dif-
ferent between the two groups but also median time to 
progression. Additionally, both authors reported that on 
multivariate analysis, the response of CA 19-9  1 20% dur-
ing gemcitabine chemotherapy was a strong and inde-
pendent predictor of survival  [46, 49] . This observation 
was also confirmed by Maisey et al.  [52] with their data 
showing that a fall of 20% in CA 19-9 levels following the 
start of a gemcitabine- and/or 5-FU-based chemotherapy 
is an independent prognostic factor for overall survival 
(HR 1.9, CI 1.1–3.4, p = 0.019) on multivariate analysis. 
Thus, not only pretreatment CA 19-9 levels but also a CA 
19-9 response under chemotherapy may serve as an inde-
pendent prognostic factor regarding survival. 
 Correlation of CA 19-9 Changes during 
Chemotherapy with Objective Tumor Response 
 Up to now, it has not been clearly defined whether CA 
19-9 changes may be used as a parameter to monitor 
treatment response in patients with PC treated with che-
motherapy. Several studies reported that patients with an 
objective (radiographic) tumor response also often show 
a decline in serum CA 19-9 levels. But not all patients ob-
jectively responding to therapy do so and especially in 
patients with stable or progressive disease, the additional 
prognostic information obtained by serum tumor mark-
er kinetics is unclear. In patients treated with gemcitabi-
ne and cisplatin, 8 out of 10 who achieved a radiological 
CR or PR had a decline of CA 19-9  1 50% during treat-
ment, which was also seen in 10 out of 15 patients with 
disease stabilization and in 5 out of 12 patients (42%) with 
progressive disease  [37] . Heinemann et al.  [54]  reported 
21 patients treated with the same combination regimen: 
in this study all 4 patients with CR reached normal CA 
19-9 values during the course of treatment and all pa-
tients with PR showed a CA 19-9 decrease. Among pa-
tients with SD, CA 19-9 transiently decreased in 7/8 pa-
tients and in the group with PD CA 19-9 initially in-
creased in 4/5 patients. In the updated data from this 
trial, all patients with CR and 10/11 patients with PR were 
considered CA 19-9 responders (defined by a decline 
 1 50% within 2 months of treatment), but also 12 out of 
27 patients with PD on imaging techniques showed a bio-
chemical response characterized by decreases in CA 19-9 
levels (8 of them qualified as CA 19-9 responders). This 
subgroup of patients (with PD on imaging and CA 19-9 
response) had a significantly longer median survival than 
CA 19-9 nonresponders with PD (247 vs. 142 days, p = 
0.04). The sensitivity of correlating CA 19-9 response and 
CT findings in this study was 93.3% with only a low spec-
ificity of 53.2%, respectively. The positive predictive val-
ue of a CA 19-9 response was 32.5% with a high negative 
predictive value of 97.1%  [48] . Comparable results were 
obtained from two trials with single-agent gemcitabine 
treatment in patients with PC. All patients with CR or PR 
were classified as CA 19-9 responder (defined by a de-
crease  1 20% after 8 weeks of chemotherapy), but in both 
trials a CA 19-9 response in patients with PD on imaging 
modalities (2/7 and 2/20, respectively) was also seen  [46, 
49] . 
 In two clinical phase II and III trials evaluating the ef-
ficacy of the irinotecan/gemcitabine combination in the 
treatment of advanced PC, CA 19-9 monitoring – as a 
potential parameter for treatment efficacy – was includ-
ed. In the phase II part with 44 patients, Rocha Lima et 
al.  [39]  found a significant correlation between propor-
tional changes in CA 19-9 and radiological changes of the 
tumor with regard to the extent of change (r = 0.67) and 
also a good correlation between CA 19-9 progression and 
time to progression (r = 0.89) with CA 19-9 progression 
preceding radiographic progression in most of the pa-
tients. The overall diagnostic accuracy (determined in 
the phase III trial) of CA 19-9 values in the prediction of 
tumor response or progression was low (57.6 and 59.0%, 
respectively). Nevertheless, a CA 19-9 decline of less than 
50% may predict a lack of objective treatment response 
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(negative predictive value: 94.8%) and a CA 19–9 pro-
gression (increase  1 50%) may be predictive for objective 
disease progression (positive predictive value: 82.8%) 
 [55] . Previously, Gogas et al.  [45]  reported a negative pre-
dictive value of serial CA 19-9 kinetics for an objective 
partial response, stable disease or progressive disease of 
87, 41 and 90%, respectively.  
 Discussion 
 Up to now, CA 19-9 has been the most widely used 
‘standard’ serum tumor marker in patients with PC. It 
has quite a good diagnostic sensitivity and specificity [for 
review, see Steinberg   [9] ) with some known limitations, 
e.g. in patients with (benign) jaundice, pancreatitis or 
other gastrointestinal malignancies. For monitoring pa-
tients under therapy and for assessing prognosis, the rou-
tine use of CA 19-9 is not generally recommended at pres-
ent  [56] . Nevertheless, there are several studies showing 
that CA 19-9 has the potential to become a clinically use-
ful prognostic marker in patients with PC. In patients 
undergoing surgery for PC especially the decline of ele-
vated baseline levels after operation may help to identify 
patients with a prolonged disease-free and overall sur-
vival  [19] . Thus, CA 19-9 can provide useful additional 
information in therapeutic decision, e.g. in patients with 
a lack of CA 19-9 decline after tumor resection as candi-
dates for different adjuvant treatment strategies. 
 In patients treated with CRT, pre- and posttreatment 
CA 19-9 levels show an association with overall survival 
 [28, 31, 32] . Whether a biochemical treatment response, 
defined by declining CA 19-9 values under therapy, has 
an influence on survival is not yet clear. In the study of 
Micke et al.  [32]  a decrease of the serum tumor marker CA 
19-9 during therapy was an independent prognostic factor 
regarding survival on multivariate analysis, but Wilkows-
ki et al.  [30]  in their study could not confirm that the bio-
chemical response status has an influence on survival. 
 Similar to the observations in patients treated with 
surgery or CRT, pretreatment CA 19-9 baseline values 
were found to have a strong and independent prognostic 
significance for patients treated with systemic chemo-
therapy  [47, 52, 53] . But as shown in  table 1 , different clin-
ical studies reported a wide discrepancy for a CA 19-9 
cutoff level (200–1,212 U/ml) that makes identifying 
prognostic relevant subgroups possible. Most investiga-
tors defined the cutoff point (that separates the two sub-
groups with a different survival prognosis in each indi-
vidual trial) as the median of the CA 19-9 serum values 
in their patient population. Thus, it is not surprising that 
in clinical trials that included patients with resectable 
disease  [16, 17] lower median CA 19-9 cutoff points were 
defined than in studies that enrolled only patients with 
an advanced stage of disease  [47, 52] . In order to achieve 
a unique definition of (individualized and stage-adapted) 
cutoff points that will help to separate different prognos-
tic subgroups, a controlled prospective evaluation is nec-
essary. Only a prospective clinical trial that defines fixed 
CA 19-9 cutoff points (e.g. 1,000 U/ml for patients with 
metastatic disease) will be able to lead to a unique defini-
tion of this clinical relevant issue. 
 Furthermore, several studies clearly showed that pa-
tients classified as CA 19-9 responders to chemotherapy 
have a significantly longer median survival than CA 19-9 
nonresponders ( table 4 ). Nevertheless, the role of CA 19-9 
in monitoring (objective) treatment efficacy remains un-
clear. In most cases, patients with an objective complete 
or partial remission also show a biochemical treatment 
efficacy by decreasing CA 19-9 levels under chemothera-
py. Especially the negative predictive value of CA 19-9 
kinetics for a remission or for tumor progression seems 
to be good with levels up to 90%  [48, 55] , but with certain 
limitations regarding the overall diagnostic accuracy of 
CA 19-9 values in the prediction of tumor response or 
progression  [55] . Especially in patients with stable or pro-
gressive disease, the additional prognostic information of 
serial CA 19-9 changes is not defined. However, it was 
demonstrated that patients classified as CA 19-9 respond-
ers and with a documented disease progression on con-
ventional imaging techniques had a significantly longer 
survival than CA 19-9 nonresponders with progressive 
disease  [48] . It seems that a biochemical treatment effect 
has a prognostic meaning regarding survival, despite a 
documented disease progression on imaging. Thus, ther-
apeutic consequences may also occur, e.g. that such a sub-
group of patients may benefit from active second-line 
treatment regimens. Nevertheless, a CA 19-9 monitoring 
in patients with advanced PC undergoing palliative che-
motherapy should still be regarded as one additional tool 
– besides imaging and clinical condition of the patient – 
for treatment decisions.  
 Future Perspectives 
 As a first step for standardization, a unique assay 
should be used in clinical studies incorporating CA 19-9 
measurements in order to generate comparable and reli-
able results. A standardized CA 19-9 measurement should 
 Boeck  /Stieber  /Holdenrieder  /Wilkowski  /
Heinemann  
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also be included (e.g. as a secondary endpoint) in future 
phase III trials in order to confirm the data summarized 
here on the level of randomized trials with a large number 
of patients. In fact, only one phase III trial has reported 
CA 19-9 values as a prognostic factor up to now  [53] . Re-
garding the obvious prognostic impact of CA 19-9 base-
line levels in patients receiving systemic chemotherapy, a 
use of this tumor marker as a parameter of stratification 
in phase III trials appears to be justified.  
 Furthermore, a unique definition of a ‘CA 19-9 re-
sponse’ is also required for monitoring treatment efficacy 
with CA 19-9 as a (biochemical) surrogate marker. A ‘CA 
19-9 responder’ must not necessarily be defined as a pa-
tient with a CA 19-9 reduction of at least 50% of the pre-
treatment level within 2 months after the initiation of 
treatment  [44, 47] . Several other groups clearly showed 
that also a CA 19-9 reduction with cutoff levels of 15, 20 
or 25% was able to identify subgroups of patients with a 
prognostic favorable outcome regarding median overall 
survival (see  table 4 ). Thus, a cutoff point of a CA 19-9 
decline of more than 20% after 8 weeks of chemothera-
peutic treatment seems to be sufficient to define a (clini-
cally relevant) subgroup of patients with a prolonged sur-
vival. Based on the data summarized here, we recom-
mend this definition of a ‘CA 19-9 responder’ for further 
prospective chemotherapeutic trials in patients with ad-
vanced PC. Despite these efforts regarding standardiza-
tion, it still remains important to remember other limita-
tions of serum tumor markers when monitoring a patient 
with PC: not only the alteration of CA 19-9 levels by dif-
ferent pathological processes and conditions (especially 
jaundice) but also the theoretical possibility of novel 
agents (e.g. monoclonal antibodies) interfering with the 
CA 19-9 assay must be considered carefully.  
 Tumor markers and other biological markers have the 
potential to become useful diagnostic and prognostic pa-
rameters in the treatment of patients with cancer. Serum 
tumor markers are easy to sample and their determina-
tion is – compared e.g. to radiological imaging modalities 
– cost effective and quick. In PC, new markers like ge-
netic alterations and also other serum tumor antigens 
(e.g. CA 72-4 or CA 242) must be further investigated and 
both their diagnostic and prognostic role must be defined 
by comparative studies with CA 19-9  [57, 58] . Pretreat-
ment alterations (like S100A6  [59] ) as well as kinetics of 
novel apoptotic markers like nucleosomes  [60] during 
therapy may have prognostic significance, and thus may 
serve as helpful tools in therapeutic decisions in this 
harmful disease. Additionally, different laboratory meth-
ods for the determination of systemic inflammatory re-
sponses (e.g. by cytokines or C-reactive protein) in pa-
tients with PC will probably also serve as relevant predic-
tors of outcome  [61, 62] . 
 Conclusion 
 The serum tumor marker CA 19-9 has the potential to 
permit both the assessment of prognosis and monitoring 
of patients with pancreatic adenocarcinoma. In patients 
with advanced disease, pretreatment CA 19-9 levels can 
provide prognostic information regarding overall surviv-
al and a decline of CA 19-9 (‘CA 19-9 responder’) under 
chemotherapy may serve as a useful additional tool for 
the go/no-go question in treatment decisions. A stan-
dardized measurement of CA 19-9 and a unique defini-
tion of CA 19-9 response to treatment are strongly recom-
mended for further prospective trials. 
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